Lung Tissue Injury as an Atypical Response to Nivolumab in Non-Small Cell Lung Cancer

Am J Respir Crit Care Med. 2017 Nov 15;196(10):1349-1350. doi: 10.1164/rccm.201705-0875IM.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antibodies, Monoclonal / adverse effects*
  • Antineoplastic Agents / adverse effects*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Humans
  • Lung / diagnostic imaging*
  • Lung / drug effects*
  • Lung Neoplasms / drug therapy*
  • Male
  • Nivolumab
  • Tomography, X-Ray Computed

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Nivolumab